Isotechnika reports kidney transplant data

Isotechnika (TSX:ISA) said preliminary data from a Phase IIb trial of ISA247 to prevent renal transplant rejection

Read the full 172 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE